Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.68 USD | +6.52% | +0.26% | +13.48% |
Financials (USD)
Sales 2024 * | 34.43M | Sales 2025 * | 19.08M | Capitalization | 448M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -108M | EV / Sales 2024 * | 9.25 x |
Net cash position 2024 * | 130M | Net cash position 2025 * | 10.2M | EV / Sales 2025 * | 23 x |
P/E ratio 2024 * |
-4.95
x | P/E ratio 2025 * |
-4.48
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.61% |
Latest transcript on Fulcrum Therapeutics, Inc.
1 day | -2.83% | ||
1 week | -6.36% | ||
Current month | +1.12% | ||
1 month | +0.98% | ||
3 months | -29.17% | ||
6 months | +48.97% | ||
Current year | +6.81% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 7.68 | +6.52% | 846 322 |
24-05-24 | 7.21 | -2.83% | 305,764 |
24-05-23 | 7.42 | -3.76% | 379,235 |
24-05-22 | 7.71 | +0.92% | 266,404 |
24-05-21 | 7.64 | -0.78% | 570,501 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.81% | 448M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.93% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- FULC Stock